Cartesian Therapeutics Inc
NASDAQ:RNAC
Cartesian Therapeutics Inc
Research & Development
Cartesian Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cartesian Therapeutics Inc
NASDAQ:RNAC
|
Research & Development
-$54.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Cartesian Therapeutics Inc
Glance View
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.
See Also
What is Cartesian Therapeutics Inc's Research & Development?
Research & Development
-54.7m
USD
Based on the financial report for Sep 30, 2025, Cartesian Therapeutics Inc's Research & Development amounts to -54.7m USD.
What is Cartesian Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
0%
Over the last year, the Research & Development growth was 2%. The average annual Research & Development growth rates for Cartesian Therapeutics Inc have been 9% over the past three years .
